Related Experiment Video
Updated: Aug 29, 2026

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia
Published on: April 19, 2024
Abstract:
KMD 3213 [silodosin, KAD 3213] is an orally active alpha(1)-adrenoceptor antagonist under development with Kissei (Japan) for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Daiichi Pharmaceutical and Kissei are conducting phase III trials in Japan, while Kissei's US subsidiary, Kissei Pharma USA Inc., has completed early phase II trials with favourable results for the treatment of dysuria associated with benign prostatic hyperplasia (BPH). Kissei expects to file an NDA application in Japan in July 2004. Daiichi is also preparing a phase I trial in China with this compound for the treatment of dysuria associated with benign prostatic hyperplasia. According to Kissei's 2003 Annual Report, they are currently preparing to license out the development and marketing rights for KMD 3213 in Europe and North America. In March 2002, Daiichi predicted that KMD 3213 has the potential to reach peak sales of approximately 10 billion Japanese yen.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Dosage Regimens: Designs and Approaches
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Antihypertensive Drugs: Thiazide-Class Diuretics
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
